RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      뇌졸중 최신지견 2009: 뇌졸중의 급성기 치료 및 이차예방 = Stroke Update 2009: Acute Ischemic Stroke and Secondary Stroke Prevention

      한글로보기

      https://www.riss.kr/link?id=A101608238

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      There were several positive clinical trials with new anticoagulants and antiplatelet agents which will affect on the guideline of the secondary stroke prevention. Dabigatran, an oral direct thrombin inihibitor, had better clinical outcomes than warfarin in the prevention of cardiovascular events in the patients with atrial fibrillation. Ticagrelor and prasugrel are new antiplatelet agents. They successfully reduced cardiovascular events after acute myocardial infarction without increase bleeding complications compared to clopidogrel. The effects of platelet inhibition of those thienopyridine antiplatelet agents were influenced by the usage of proton pump inhibitor owever, there are no direct supporting evidences to avoid concomitant use of prohibition of proton pump inhibitors and thienopyridines. Genetic polymorphisms of cytochrome P450 2C19, which affects on the metabolism of thienopyridines, affect on the antiplatelet effects of thienopyridines and clinical outcomes. One small clinical trial showed that niacin was better in the prevention of progression of intima-medial thickness of common carotid artery than ezetimibe.
      번역하기

      There were several positive clinical trials with new anticoagulants and antiplatelet agents which will affect on the guideline of the secondary stroke prevention. Dabigatran, an oral direct thrombin inihibitor, had better clinical outcomes than warfar...

      There were several positive clinical trials with new anticoagulants and antiplatelet agents which will affect on the guideline of the secondary stroke prevention. Dabigatran, an oral direct thrombin inihibitor, had better clinical outcomes than warfarin in the prevention of cardiovascular events in the patients with atrial fibrillation. Ticagrelor and prasugrel are new antiplatelet agents. They successfully reduced cardiovascular events after acute myocardial infarction without increase bleeding complications compared to clopidogrel. The effects of platelet inhibition of those thienopyridine antiplatelet agents were influenced by the usage of proton pump inhibitor owever, there are no direct supporting evidences to avoid concomitant use of prohibition of proton pump inhibitors and thienopyridines. Genetic polymorphisms of cytochrome P450 2C19, which affects on the metabolism of thienopyridines, affect on the antiplatelet effects of thienopyridines and clinical outcomes. One small clinical trial showed that niacin was better in the prevention of progression of intima-medial thickness of common carotid artery than ezetimibe.

      더보기

      참고문헌 (Reference)

      1 Wallentin L, "Ticagrelor versus clopidogrel in patients with acute coronary syndromes" 361 : 1045-1057, 2009

      2 Montalescot G, "TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITONTIMI 38): double-blind, randomised controlled trial" 373 : 723-731, 2009

      3 Wiviott SD, "TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes" 357 : 2001-2015, 2007

      4 Lassen MR, "RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty" 358 : 2776-2786, 2008

      5 Connolly SJ, "RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation" 361 : 1139-1151, 2009

      6 van de Beek D, "Preventive antibiotics for infections in acute stroke: a systematic review and meta-analysis" 66 : 1076-1081, 2009

      7 O’Donoghue ML, "Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials" 374 : 989-997, 2009

      8 Wiviott SD, "PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation- Thrombolysis in Myocardial Infarction 44 trial" 116 : 2923-2932, 2007

      9 den Hertog HM, "PAIS Investigators. The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial" 8 : 434-440, 2009

      10 Diener HC, "MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial" 364 : 331-337, 2004

      1 Wallentin L, "Ticagrelor versus clopidogrel in patients with acute coronary syndromes" 361 : 1045-1057, 2009

      2 Montalescot G, "TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITONTIMI 38): double-blind, randomised controlled trial" 373 : 723-731, 2009

      3 Wiviott SD, "TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes" 357 : 2001-2015, 2007

      4 Lassen MR, "RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty" 358 : 2776-2786, 2008

      5 Connolly SJ, "RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation" 361 : 1139-1151, 2009

      6 van de Beek D, "Preventive antibiotics for infections in acute stroke: a systematic review and meta-analysis" 66 : 1076-1081, 2009

      7 O’Donoghue ML, "Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials" 374 : 989-997, 2009

      8 Wiviott SD, "PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation- Thrombolysis in Myocardial Infarction 44 trial" 116 : 2923-2932, 2007

      9 den Hertog HM, "PAIS Investigators. The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial" 8 : 434-440, 2009

      10 Diener HC, "MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial" 364 : 331-337, 2004

      11 Simon T, "French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events" 360 : 363-375, 2009

      12 Taylor AJ, "Extended-release niacin or ezetimibe and carotid intima-media thickness" 361 : 2113-2122, 2009

      13 ACTIVE Investigators, "Effect of clopidogrel added to aspirin in patients with atrial fibrillation" 360 : 2066-2078, 2009

      14 Collet JP, "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study" 373 : 309-317, 2009

      15 Bhatt DL, "CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events" 354 : 1706-1717, 2006

      16 Mega JL, "ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial" 374 : 29-38, 2009

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2014-11-01 평가 SCIE 등재 (기타) KCI등재
      2013-01-01 평가 등재후보학술지 유지 (기타) KCI등재후보
      2011-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 3.63 0.55 3.13
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      2.37 1.91 1.175 0.1
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼